Bristol Myers Squibb (CELG-RI) Dividends Paid - Common (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Dividends Paid - Common of $1.3 billion for Q2 2026, up 1.98% year-over-year from $1.3 billion in Q2 2025, and little changed quarter-over-quarter from $1.3 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Dividends Paid - Common (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Dividends Paid - Common for 18 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Dividends Paid - Common rose 1.98% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $5.1 billion (up 2.85% YoY), while the FY2025 annual figure was $5.0 billion, up 3.74% from the prior year.
- Dividends Paid - Common held at $1.3 billion in Q2 2026 per CELG-RI's latest filing, from $1.3 billion in the prior quarter.
- Across five years, Dividends Paid - Common topped out at $1.3 billion in Q2 2026 and bottomed at $12.0 million in Q2 2022.
- Historically, Dividends Paid - Common has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
- On a YoY basis, Dividends Paid - Common climbed as much as 9875.0% in 2023 and fell as far as 0.93% in 2023.
- Bristol Myers Squibb's Dividends Paid - Common stood at $1.1 billion in 2022, then gained by 1.31% to $1.2 billion in 2023, then gained by 5.0% to $1.2 billion in 2024, then grew by 3.61% to $1.3 billion in 2025, then advanced by 1.98% to $1.3 billion in 2026.
- Business Quant data shows CELG-RI's Dividends Paid - Common at $1.3 billion in Q2 2026, $1.3 billion in Q1 2026, and $1.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Paid (Common) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 3.23 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.07 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.14 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 2.87 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 6.58 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.36 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.03 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.45 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 1.29 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.29 Bn |
| Jun 30, 2026 | 1.29 Bn |
| Mar 31, 2026 | 1.28 Bn |
| Mar 31, 2026 | 1.28 Bn |
| Dec 31, 2025 | 1.26 Bn |
| Dec 31, 2025 | 1.26 Bn |
| Sep 30, 2025 | 1.26 Bn |
| Sep 30, 2025 | 1.26 Bn |
| Jun 30, 2025 | 1.26 Bn |
| Jun 30, 2025 | 1.26 Bn |
| Mar 31, 2025 | 1.26 Bn |
| Mar 31, 2025 | 1.26 Bn |
| Dec 31, 2024 | 1.22 Bn |
| Dec 31, 2024 | 1.22 Bn |
| Sep 30, 2024 | 1.22 Bn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.22 Bn |
| Mar 31, 2024 | 1.21 Bn |
| Mar 31, 2024 | 1.21 Bn |